Bone Marrow Dosimetry in Radioiodine (I-131) Treatment
PDF

Review

Bone Marrow Dosimetry in Radioiodine (I-131) Treatment

Nucl Med Semin 2025;11(1):15-20 DOI: 10.4274/nts.galenos.2025.91300
PDF
Permissions

Abstract

In radioiodine therapies, the most radiosensitive tissue in the body is the red bone marrow. The maximum iodine-131 activity is calculated through dosimetry to ensure that the blood-representing the dose-limiting organ, the bone marrow-receives a dose below 2 Gy during treatment. Dosimetry involves calculations based on measuring blood samples collected from the patient after administering approximately 74 MBq (2 mCi) of radioiodine, using a gamma counter.

Keywords: Radioiodine treatment, bone marrow dosimetry, dosimetry on I-131 treatment

References

1

Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171-182.

2

Leeper RD. Thyroid cancer. Medical Clinics of North America. 1985;69:1079-1096.

3

Kabasakal L. Teranostik yaklaşımın atası: radyoaktif iyot “radyonüklit tedavi için bir prolog”. Nuclear Medicine Seminars / Nükleer Tıp Seminerleri. 2015;2:85-91.

4

Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G; EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238-1250.

5

Lassmann M, Hänscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405-1412.

6

Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.